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A B S T R A C T
14-O-methyl (14-O-Me) group in morphine-6-O-sulfate (M6SU) or oxymorphone has been reported to be es-
sential for enhanced aﬃnity, potency and antinociceptive eﬀect of these opioids. Herein we report on the
pharmacological properties (potency, aﬃnity and eﬃcacy) of the new compound, 14-O-methylmorphine (14-O-
MeM) in in vitro. Additionally, we also investigated the antinociceptive eﬀect of the novel compound, as well as
its inhibitory action on gastrointestinal transit in in vivo. The potency and eﬃcacy of test compound were
measured by [35S]GTPγS binding, isolated mouse vas deferens (MVD) and rat vas deferens (RVD) assays. The
aﬃnity of 14-O-MeM for opioid receptors was assessed by radioligand binding and MVD assays. The anti-
nociceptive and gastrointestinal eﬀects of the novel compound were evaluated in the rat tail-ﬂick test and
charcoal meal test, respectively. Morphine, DAMGO, Ile5,6 deltorphin II, deltorphin II and U-69593 were used as
reference compounds.
14-O-MeM showed higher eﬃcacy (Emax) and potency (EC50) than morphine in MVD, RVD or [35S]GTPγS
binding. In addition, 14-O-MeM compared to morphine showed higher aﬃnity for μ-opioid receptor (MOR). In
vivo, in rat tail-ﬂick test 14-O-MeM proved to be stronger antinociceptive agent than morphine after peripheral
or central administration. Additionally, both compounds inhibited the gastrointestinal peristalsis. However,
when the antinociceptive and antitransit doses for each test compound are compared, 14-O-MeM proved to have
slightly more favorable pharmacological proﬁle.
Our results aﬃrm that 14-O-MeM, an opioid of high eﬃcacy and aﬃnity for MOR can be considered as a
novel analgesic agent of potential clinical value.
1. Introduction
The opium-derived analgesic morphine is widely used in clinic to
manage moderate to severe pain and considered to be the prototypical
non-peptide opioid agonist, with a high selectivity for the μ-opioid re-
ceptor (MOR) subtype. Besides μ-opioid receptors, mammalians are also
hosting κ-opioid receptors (KOR) and δ-opioid receptors (DOR). These
receptors are G-protein-coupled receptors (GPCR) and they are ex-
pressed at central and peripheral relay points of nociceptive transmis-
sion (Fürst, 1999) and activated by endogenous or exogenous opioids.
Upon their activation besides antinociceptive eﬀect other measurable
unwanted actions like respiratory depression, sedation or constipation
are evoked (Debono et al., 2013; Koob et al., 1998).
One of the main goals of opioid researchers is to ﬁnd opioid ligands
of better pharmacological proﬁles than that of the currently available.
14-methoxy analogues of oxymorphone (14-O-methyloxymorphone) or
morphine-6-O-sulfate have been reported to have higher aﬃnity for
opioid receptors and enhanced antinociceptive action compared to the
parent compounds (Fürst et al., 2005; Khalefa et al., 2013; Lacko et al.,
2012; Spetea et al., 2004). To the best of our knowledge, the in vitro and
in vivo pharmacological proﬁle of 14-methoxy analogues of morphine,
particularly, 14-O-methylmorphine (Fig. 1) has not been reported yet.
Therefore, the aim of the present work was to synthesize 14-O-
methylmorphine, assess its receptor preference (selectivity and aﬃnity)
for opioid receptors in biological (MVD, mouse vas deferens) and bio-
chemical (equilibrium competition binding) assays. Further aim was to
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determine the potency and eﬃcacy of 14-O-methylmorphine and
compare them to the parent compound, morphine and to other, selec-
tive µ-, δ- and к-opioid receptor agonists, such as [D-Ala2,N-Me-
Phe4,Gly-ol5]enkephalin (DAMGO), deltorphin II and U-69593, re-
spectively, in mouse and rat vas deferens and functional [35S]GTPγS
binding. Further objective was to determine the antinociceptive eﬀect
of 14-O-methylmorphine, as well as its inhibitory eﬀect on gastro-
intestinal transit applying rat tail-ﬂick and charcoal meal assays, re-
spectively and compare them to the eﬀects of morphine.
2. Materials and methods
2.1. Animals
Male NMRI mice (35–45 g) for experiments designed for MVD and
male Wistar rats for rat tail-ﬂick test (140–240 g) and for RVD and
gastrointestinal charcoal meal test (160–260 g) were used. Mice and
rats were obtained from Toxi-Coop Zrt. (Budapest, Hungary) and the
Animal House of Semmelweis University (Budapest, Hungary), respec-
tively. Animals were housed in the local animal house of the
Department of Pharmacology and Pharmacotherapy, Semmelweis
University (Budapest, Hungary).
For in vitro receptor binding assays male and female Wistar rats
(250–300 g body weight) and male guinea pigs (~400–700 g body
weight, LAL/HA/BR strain) were used. Rats were purchased from and
housed in the local animal house of the Biological Research Centre of
the Hungarian Academy of Sciences (Szeged, Hungary), while guinea
pigs were purchased from and housed in LAB-ÁLL Bt. (Budapest,
Hungary).
The animals were kept in a temperature controlled room (21–24 °C)
under a 12:12 light and dark cycle and were provided with water and
food ad libitum. All housing and experiments were handled in ac-
cordance with the European Communities Council Directives (2010/
63/EU), the Hungarian Act for the Protection of Animals in Research
(XXVIII.tv. 32.§) and local animal care committee (PEI/001/276-4/
2013). All the researchers did the best eﬀort to minimize the number of
animals and their suﬀering.
2.2. Chemicals
14-O-methylmorphine (Fig. 1) was synthesized as described under
Section 2.3. Tris-HCl, EGTA, NaCl, MgCl2 × 6H2O, GDP, the GTP
analogue GTPγS, the DOR and KOR antagonist naltrindole and norbi-
naltorphimine, respectively and the KOR agonist U-69593 were pur-
chased from Sigma-Aldrich (Budapest, Hungary). The MOR selective
antagonist cyprodime was provided by Dr. Helmut Schmidhammer
(Department of Pharmacy, University of Innsbruck, Austria) and the
MOR agonist enkephalin analogue Tyr-D-Ala-Gly-(NMe)Phe-Gly-ol
(DAMGO) and the DOR selective agonist deltorphin II (Delt II) were
obtained from Bachem Holding AG (Bubendorf, Switzerland) and Tocris
Bioscience (through Biomedica Hungária Kft., Budapest, Hungary). The
selective DOR agonist Ile5,6-deltorphin II (IleDelt II) was synthesized in
the Laboratory of Chemical Biology group of the Biological Research
Centre of the Hungarian Academy of Sciences (Szeged, Hungary). The
non-selective opioid receptor antagonist naloxone was kindly provided
by the company Endo Laboratories DuPont de Nemours (Wilmington,
DE, USA). Morphine hydrochloride was obtained from (Alkaloida-ICN,
Tiszavasvári, Hungary). Ligands were dissolved in water and were
stored in 1 mM stock solution at 20 °C for in vitro tests. Ligands used for
in vivo assays were dissolved in saline prior to the experiments.
The radiolabeled GTP analogue, [35S]GTPγS (speciﬁc activity: 1000
Ci/mmol) was purchased from Hartmann Analytic (through Izotóp
Intézet Kft., Budapest, Hungary). [3H]DAMGO (speciﬁc activity:
38.8 Ci/mmol), [3H]IleDelt II (speciﬁc activity: 19,6 Ci/mmol) were
radiolabeled by the Laboratory of Chemical Biology group in BRC
(Szeged, Hungary). [3H]U-69593 (speciﬁc activity: 43,6 Ci/mmol) were
purchased from PerkinElmer (through Per-Form Hungária Kft.,
Budapest, Hungary). The UltimaGold™ MV aqueous scintillation cock-
tail was purchased from PerkinElmer (through Per-Form Hungária Kft.,
Budapest, Hungary).
2.3. Chemistry
14-O-methylmorphine was synthesized as described previously
(Lacko et al., 2012). Brieﬂy, 14-OH-codeinone was used as the starting
material (Fig. 2). O-methylation was carried out by dimethyl sulfate in
the presence of sodium hydride in N,N-dimethylformamide (Kobylecki
et al., 1982; Razdan and Ghosh, 1980). 14-O-methylcodeinone was
selectively demethylated in the 3-O position by reﬂuxing in aqueous
hydrogen bromide (Schmidhammer et al., 1990). The resulting 14-O-
methylmorphinone was reduced by sodium borohydride in methanol to
give 14-O-methylmorphine.
NMR data: Mp.: 221–223 °C. 1H NMR (600 MHz, CDCl3): δ = 6.62
(d, J = 8.1 Hz, H-2, 1H), 6.48 (d, J = 8.1 Hz, H-1, 1H), 5.88 (d, J =
9.9 Hz, H-7, 1H), 5.47 (dd, J = 9.9, 3.2 Hz, H-8, 1H), 4.87 (d, J =
6.4 Hz, H-5, 1H), 4.60 (m, H-6, 1H), 3.20 (s, 14-OMe, 3H), 2.44 (s,
NMe, 3H) ppm. 13C NMR (150 MHz, CDCl3): δ = 144.6, 138.6, 137.8,
132.8, 129.0, 126.2, 119.5, 117.1, 90.2, 74.9, 66.0, 57.4, 50.6, 47.6,
46.0, 43.3, 30.6, 29.9, 22.6 ppm.
Fig. 1. The structure of morphine and 14-O-methylmorphine (14-O-MeM).
Fig. 2. The synthesis of 14-O-methylmorphine (14-O-MeM). For further information see Section 2.3.
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2.4. Receptor binding assays
2.4.1. Membrane preparations
Rats and guinea pigs were decapitated and their brains were quickly
removed. The brains were prepared for membrane preparation ac-
cording to Benyhe and co-workers (Benyhe et al., 1997). The brain
membrane homogenates were partly used for competition binding ex-
periments and partly were further prepared for the [35S]GTPγS binding
assays according to Zádor and co-workers (Zádor et al., 2014). In brief,
ﬁrstly the brains were homogenized, centrifuged in ice-cold 50 mM
Tris-HCl (pH 7.4) buﬀer and incubated at 37 °C for 30 min in a shaking
water-bath (for details see Benyhe et al., 1997). After incubation the
centrifugation was repeated as described before and the ﬁnal pellet was
suspended in 50 mM Tris-HCl pH 7.4 buﬀer containing 0.32 M sucrose
and stored at – 80 °C for further use. For the [35S]GTPγS binding ex-
periments the ﬁnal pellet of rat brain membrane homogenate was
suspended in ice-cold TEM (Tris-HCl, EGTA, MgCl2) buﬀer and stored at
– 80 °C for further use.
2.4.2. Radioligand competition binding assays
In competition binding assays the aﬃnity of an unlabeled com-
pound is analyzed by measuring radioligand speciﬁc binding in the
presence of increasing concentrations of the unlabeled compound in
question (Frey and Albin, 2001).
Aliquots of frozen rat and guinea pig brain membrane homogenates
were centrifuged (40,000 g, 20 min, 4 °C) to remove sucrose and the
pellets were suspended in 50 mM Tris-HCl buﬀer (pH 7.4). Brain
membranes homogenates containing 0.3–0.5 mg/ml of protein were
incubated in the presence of increasing concentrations (0.1 nM-10 µM)
of 14-O-methylmorphine or morphine or with the equivalent homo-
logues ligand of the radioligands (DAMGO, Ile5,6-deltorphin II and U-
69593 for control) with ~ 1–3 nM concentrations of the given radi-
oligand. The incubation temperatures and times were dependent from
the radioligand and were the following: [3H]DAMGO and [3H]
Ile5,6-deltorphin II in 35 °C for 45 min, [3H]U-69593 in 30 °C for
30 min. Experiments with [3H]U-69593 were performed in guinea pig
brain membrane homogenates, since the guinea pig brain has sig-
niﬁcantly more κ-opioid receptors than the rat brain, while the rest of
the radioligands ([3H]DAMGO and [3H]Ile5,6-deltorphin II) were ex-
amined in rat brain membrane homogenates. The non-speciﬁc and total
binding were determined in the presence of 10 μM unlabeled naloxone
and in the absence of unlabeled compounds, respectively. The reaction
was terminated by rapid ﬁltration under vacuum (Brandel M24R Cell
Harvester), and washed three times with 5 ml ice-cold 50 mM Tris-HCl
through Whatman GF/C ([3H]DAMGO, [3H]Ile5,6-deltorphin II or GF/B
([3H]U-69593)) glass ﬁbers (GE Healthcare Life Sciences through Izinta
Kft., Budapest, Hungary). The radioactivity of the ﬁlters was detected in
UltimaGold™ MV aqueous scintillation cocktail with Packard Tricarb
2300TR liquid scintillation counter. The competition binding assays
were performed in duplicate and repeated at least three times.
2.4.3. Functional [35S]GTPγS binding assays
In [35S]GTPγS binding experiments we measure the GDP→GTP
exchange of the Gαi/o protein in the presence of a given ligand to
measure ligand potency and the maximal eﬃcacy of receptors G-protein
(Strange, 2010). The nucleotide exchange is monitored by a radio-
active, non-hydrolysable GTP analogue, [35S]GTPγS.
The functional [35S]GTPγS binding experiments were performed as
previously described (Sim et al., 1995; Traynor and Nahorski, 1995),
with modiﬁcations. Brieﬂy the rat or guinea pig brain membrane
homogenates containing ~10 μg/ml protein were incubated at 30 °C for
60 min in Tris-EGTA buﬀer (pH 7.4) composed of 50 mM Tris-HCl,
1 mM EGTA, 3 mM MgCl2, 100 mM NaCl, containing 0.05 nM [35S]G-
TPγS and increasing concentrations (0.1 nM-10 µM) of 14-O-methyl-
morphine, morphine, DAMGO, deltorphin II or U-69593 in the presence
or absence of 10 µM cyprodime, naltrindole or norbinaltorphimine and
excess GDP (30 μM) in a ﬁnal volume of 1 ml. 14-O-methylmorphine
and morphine were incubated both with guinea pig and rat brain
membrane homogenates, while experiments with U-69593 and norbi-
naltorphimine were performed only with guinea pig brain membrane
homogenates.
Total binding was measured in the absence of test compounds, while
non-speciﬁc binding was determined in the presence of 10 μM un-
labeled GTPγS. The bound and unbound [35S]GTPγS was separated as
described in Section 2.4.2 through Whatmann GF/B glass ﬁbers (GE
Healthcare Life Sciences through Izinta Kft., Budapest, Hungary). The
radioactivity of the ﬁlters was also detected as described in Section
2.4.2. [35S]GTPγS binding experiments were performed in triplicates
and repeated at least three times.
2.5. Isolated organs
2.5.1. Mouse vas deferens
Vasa deferentia were taken out from male mice. The preparation and
the experimental procedures were done as described previously (Rónai
et al., 1977). Brieﬂy, vasa deferentia were cleaned out from tissues and
suspended between two electrodes in organ baths of 5 ml volume with
0.1 g initial tension. The upper and the lower electrodes have ring and
straight form, respectively. The organ baths were ﬁlled with Mg2+ free
Krebs solution, of the following composition (mM/L): NaCl, 118.0; Na-
HCO3, 25.0; KCl, 4.7; KH2PO4, 1.2; glucose, 11.0; CaCl2, 2.5 aerated
with carbogen (95% O2 + 5% CO2) and kept at 31 °C. The stimulation
parameters were as follows: ﬁeld stimulation, pairs (100 ms pulse dis-
tance) of rectangular impulses (1 ms pulse width, 9 V/cm i.e. supra-
maximal intensity) were repeated by 10 s. The muscle contractions
were monitored by computer.
2.5.2. Rat vas deferens
Vasa deferentia were removed from Wistar male rats and the ex-
perimental procedure was as described for mouse vas deferens, with the
following modiﬁcations: use of Krebs solution, 0.5 g initial tension and
the electrical ﬁeld stimulation (pulse width,1 ms; intensity, 9 V/cm)
was delivered at 0.1 Hz frequency.
2.5.3. Experimental paradigms of mouse and rat vas deferens
The experimental paradigm was similar as described previously
(Lacko et al., 2012). Brieﬂy, after the equilibration time (30–40 min
and 90–120 min for mouse vas deferens and rat vas deferens respectively)
the ﬁrst dose of agonist was added and the concentration-eﬀect curves
were constructed in a cumulative manner. After that, the preparations
were washed and allowed to regain their pre-drug twitch height. Then
vasa deferentia were equilibrated with antagonist for 20 min, and
without washing a single concentration of agonist was added. To de-
termine dissociation constants of the antagonist, dose ratio (DR) values
were obtained by the single-dose method described by Kosterlitz and
Watt (1968).
2.6. Antinociceptive tests (rat tail-ﬂick test)
Rat tail-ﬂick test was performed in order to analyze the anti-
nociceptive properties of 14-O-methylmorphine. The test compounds
were dissolved in saline and injected s.c. into the animals. The ex-
periments were carried out as described earlier (Fürst et al., 1993).
Brieﬂy, a beam of light was focused onto the dorsum of the lower third
of the rat tail. Then, the time latencies until the rats ﬂick their tales
were determined before (baseline) and after injection of the test com-
pounds. Twice of the baseline latency was used as an arbitrary cut oﬀ
time in order to avoid tissue damage. The antinociceptive activity was
assessed 30, 60 and 120 min after s.c. drug administration and 10, 20,
30 and 60 min after i.c.v. administration.
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2.7. Determination the eﬀect of 14-O-methylmorphine on gastrointestinal
transit
The eﬀect of 14-O-methylmorphine compared to that of morphine
on gastrointestinal transit was determined in rats applying the charcoal
meal method, as reported previously by Vera et al. (2011), with minor
modiﬁcations. Brieﬂy, male Wistar rats were fasted 6 h prior to the
experiments, with free access to water. At the time of the experiment, a
charcoal suspension (10% charcoal in 5% gum arabic) was given in a
volume of 1 ml/animal by an oral gavage. 30 min later rats were eu-
thanized, their entire small intestines were removed, and the distance
travelled by the charcoal suspension was expressed as a percentage of
total small intestine length. 14-O-methylmorphine and morphine
(0.25 ml/100 g) were given s.c. 30 min before the application of char-
coal suspension.
2.8. Data analysis
2.8.1. Receptor binding assays
The speciﬁc binding of the radiolabeled compound ([3H]ligand,
[35S]GTPγS) was calculated by the subtraction of non-speciﬁc binding
from total binding and was given in percentage. Data was normalized to
total speciﬁc binding, which was settled 100%, which in case of
[35S]GTPγS also represents the level of basal activity of the G-protein.
Individual data sets were presented in the function of the applied ligand
concentration range in logarithm form and were individually ﬁtted with
the professional curve ﬁtting program, GraphPad Prism 5.0 (GraphPad
Prism Software Inc., San Diego, CA), using non-linear regression. In the
radioligand competition binding assays the ‘One-site competition’
equation was applied to determine IC50 (unlabeled ligand aﬃnity) and
to further calculate the inhibitory constant (Ki) value according to the
Cheng-Prusoﬀ equation (Cheng and Prusoﬀ, 1973). Selectivity ratios
were calculated based on the Ki values. In case of [35S]GTPγS binding
assays the ‘Sigmoid concentration-response’ equation was applied to
obtain the maximum G-protein eﬃcacy (Emax) and ligand potency
(EC50), respectively. These individual parameters were averaged, sta-
tistically analyzed and presented as means± S.E.M. in Tables 1 and 2.
For representation the individual speciﬁc binding data points were also
presented as means± S.E.M., ﬁtted as mentioned above and shown in
Figs. 3 and 4.
2.8.2. Mouse and rat vas deferens bioassays
Individual logarithmic concentration-response curves were con-
structed and the 50% eﬀective concentration (EC50) and maximal eﬀect
(Emax) were determined with SigmaPlot program (Systat Software Inc.,
Jose, California). In mouse vas deferens, the equilibrium dissociation
constant of naloxone (Ke) was calculated with the single-dose method as
described previously (Kosterlitz and Watt, 1968). Antagonist aﬃnities
(Ke) were calculated as follows: Ke = [antagonist concentration]/[dose
ratio-1].
2.8.3. Rat tail-ﬂick test and gastrointestinal transit
In rat tail-ﬂick test, after the dose-response curves were constructed
the dose necessary to produce a 50% eﬀect (ED50) and 95% conﬁdence
limits were calculated by the Litchﬁeld–Wilcoxon method (Litchﬁeld
and Wilcoxon, 1949).
In case of gastrointestinal transit test the doses caused 50% inhibi-
tion on gastrointestinal transit (ID50) were calculated from the linear
regression of dose-response curves and 95% conﬁdence limits were
calculated by the Litchﬁeld–Wilcoxon method (Litchﬁeld and Wilcoxon,
1949).
2.8.4. Statistical analysis
For multiple data set statistical analysis One-way ANOVA with
Tukey's multiple comparison post hoc test, while for two data sets un-
paired t-test with two-tailed P value was used. One sample t-test with a
hypothetical value of 100% or One-way ANOVA with Dunnett's mul-
tiple comparison post hoc test was applied when Ki± S.E.M. or mul-
tiple Emax± S.E.M. values, respectively were compared to the nor-
malized total speciﬁc binding (100%) obtained from receptor binding
assays. Statistical analysis was performed with GraphPad Prism 5.0
program; signiﬁcance was accepted at P<0.05 level.
3. Results
3.1. Receptor binding assays
3.1.1. Binding aﬃnity measurements in radioligand competition binding
assays
To test the opioid binding aﬃnity of 14-O-methylmorphine com-
petition binding assays were performed with µ-, δ- and к-opioid re-
ceptor speciﬁc radioligands, [3H]DAMGO, [3H]Ile5,6-deltorphin II and
[3H]U-69593, respectively. Experiments with [3H]DAMGO and [3H]
Ile5,6-deltorphin II were done in rat whole brain membrane homo-
genates, while [3H]U-69593 binding assays were performed in guinea
pig whole brain membrane homogenates. In the binding assays all
radioligand's total speciﬁc binding was reduced by their own unlabeled
homologous ligand with a Ki value in the nanomolar range (Table 1),
which indicates the adequate performance and selectivity of the radi-
oligands and are in accordance with previous data (Lacko et al., 2012).
According to the results 14-O-methylmorphine showed a very high
aﬃnity for µ-opioid receptor, since it inhibited total speciﬁc [3H]
Table 1
Inhibitory constant values (Ki± S.E.M.) and selectivity ratios of 14-O-methylmorphine (14-O-MeM) compared to morphine in competition binding assays with [3H]DAMGO, [3H]
Ile5,6-deltorphin II (IleDelt II), and [3H]U-69593, which are µ-, δ- and к-opioid receptor speciﬁc radioligands, respectively performed in rat or guinea pig brain membrane homogenates.
The unlabeled form of the radioligands are also indicated for control and for further comparison. Data were analyzed as described in Sections 2.8.1 and 2.8.4.
Compounds Ki ± S.E.M. (nM) Selectivity ratio
[3H]DAMGO (μ)1 [3H]IleDelt II (δ)1 [3H]U-69593 (κ)2 δ/μ κ/μ δ/κ
14-O-MeM 0.16± 0.03a 198.5±92.3 216.5± 60.98 1240 1356 1
(n = 5) (n = 6) (n = 3)
Morphine 0.87± 0.11 314.1±149.2 N.D.3 361 – –
(n = 7) (n = 6) (n = 4)
Homologous ligand4 0.7± 0.21 4.95± 1.61 13.34± 3.02 – – –
(n = 5) (n = 5) (n = 4)
1 Performed in rat brain membrane homogenates.
2 Performed in guinea pig brain membrane homogenates.
3 The compound did not alter signiﬁcantly (One-sample t-test) the total speciﬁc radioligand binding (100%), the Ki value cannot be interpreted (N.D.: not determined).
4 Indicates the unlabeled form of the radioligands and represent a control for the assay (μ: DAMGO δ: IleDelt II, κ: U-69593).
Note: μ, δ and κ indicates the three classic opioid receptors.
a P<0.01 compared to morphine (One-way ANOVA, Tukey's multiple comparisons post hoc test).
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DAMGO binding with a Ki of 0.16 nM (Table 1), which is a fourfold and
a ﬁvefold decrease compared to DAMGO and morphine, respectively
(Table 1). In the binding curves this was indicated by a left shift of 14-
O-methylmorphine curves compared to morphine and DAMGO
(Fig. 3A). [3H]Ile5,6-deltorphin II and [3H]U-69593 total speciﬁc
binding was reduced with a much higher Ki value in the presence of 14-
O-methylmorphine (one order of magnitude, Table 1) than in case of
[3H]DAMGO, therefore it showed lower aﬃnity towards the δ- and к-
opioid receptor (Table 1). This was also indicated by the selectivity
ratios (Table 1). Morphine reduced [3H]Ile5,6-deltorphin II speciﬁc
binding with a 1.5 fold higher Ki value compared to 14-O-methylmor-
phine (Fig. 3C, Table 1), however [3H]U-69593 speciﬁc binding re-
mained at the total level (100%) in the presence of morphine even in
the highest applied concentrations (Table 1). The δ/μ selectivity ratio of
morphine was over 300, four times lower than of 14-O-methylmorphine
(Table 1). For the averaged competition binding curves see Fig. 3.
3.1.2. Agonist activity measurements in [35S]GTPγS binding assays
To measure the agonist activity of 14-O-methylmorphine we per-
formed [35S]GTPγS binding assays, which can monitor the GPCR
mediated G-protein activation, therefore the maximum eﬃcacy and
potency of a given ligand can be determined. For comparison morphine
was also measured together with three other opioid receptor agonist
reference compounds DAMGO, deltorphin II and U-69593 selective for
µ-, δ- and к-opioid receptor, respectively. All reference compounds
performed adequately (Fig. 4A and C, Table 2) and were correspondent
with previous results (Lacko et al., 2012).
According to the results in rat brain membrane homogenates 14-O-
methylmorphine dose dependently increased [35S]GTPγS speciﬁc
binding over basal activity (Fig. 4A) with a 173.7% maximum eﬃcacy
(Emax) and 93.1 nM potency (EC50), which are improved parameters
(signiﬁcantly for Emax value) compared to morphine (145.3% and
388.1 nM; Table 2). The maximum eﬃcacy of 14-O-methylmorphine
was also higher compared to the potent µ-opioid receptor selective
agonist DAMGO and the δ-opioid receptor selective agonist deltorphin
II (165.3% and 128.9%; Table 2). In membrane homogenates of guinea
pig brain - where KORs are expressed in signiﬁcantly larger quantities
compared to the rat brain – 14-O-methylmorphine increased [35S]G-
TPγS speciﬁc binding over basal activity in a less extent and showed
signiﬁcantly lower maximum eﬃcacy compared to rat brain (173.7%
vs. 136%, Fig. 4C, Table 2.), with a lower potency, indicated by higher
EC50 values (93.1 nM vs. 324.4 nM; Table 2). Morphine displayed si-
milar potency values compared to rat brain, however morphine hardly
enhanced the basal activity of the G-protein (100%→118.8%; Fig. 4C,
Table 2), resulting a signiﬁcantly lower eﬃcacy than 14-O-methyl-
morphine (Table 2). At the same time the maximum eﬃcacy of 14-O-
methylmorphine was nearly the same as of the U-69593 (133.1% vs.
130.9%, Table 2), while displaying a lower EC50 value (324.4 nM vs.
69.7 nM, Table 2). For further information, see the averaged con-
centration-response curves of the agonists indicated in Fig. 4.
In the next step we examined the opioid receptor type selectivity of
the agonist activity of 14-O-methylmorphine. To achieve this, we
measured 14-O-methylmorphine -mediated G-protein activation in
presence of opioid receptor type selective antagonists for µ-, δ- and к-
opioid receptor, namely cyprodime, naltrindole and norbinaltorphi-
mine, respectively in 10 µM concentrations again in [35S]GTPγS
binding assays. For comparison morphine was also inhibited with cy-
prodime and naltrindole in the same concentrations, however norbi-
naltorphimine was not examined since morphine in guinea pig brain
membrane homogenates failed to show considerable activity (Fig. 4C,
Table 2). For control, the activity of the previously introduced reference
opioid agonists, DAMGO, deltorphin II and U-69593 were also ex-
amined in the presence of their corresponding selective antagonists.
According to our results, the eﬃcacy of the reference agonists was
signiﬁcantly reduced in the presence of either antagonist (Table 2),
reﬂecting their adequate activity. The [35S]GTPγS speciﬁc binding and
Table 2
Maximum G-protein eﬃcacy (Emax) and potency (EC50) of 14-O-methylmorphine (14-O-MeM) and morphine in the absence or presence of µ-, δ- and к-opioid receptor speciﬁc antagonists
cyprodime (cyp.), naltrindole (NTI) and norbinaltorphimine (nBNI), respectively in [35S]GTPγS binding assays. The table also indicates the µ-, δ- and к-opioid receptor speciﬁc agonists
DAMGO, deltorphin II (Delt II) and U-69593, respectively in the absence or presence of their corresponding receptor speciﬁc antagonists for control. Data were analyzed as described in
Sections 2.8.1 and 2.8.4.
Agonist alone + 10 μM antagonist
Compounds Emax ± S.E.M. (%) EC50 ± S.E.M. (nM) Compounds Emax ± S.E.M. (%) EC50 ± S.E.M. (nM)
14-O-MeM 173.7± 0.79a,c 93.12±18.55 + cyp. (μ) 118.7± 2.1d > 1000
(n = 6)1 (n = 5)1
– – + NTI (δ)
(n = 5)1 104.8± 3.13d N.D.3
(n = 5)2 135.6± 3.47b 324.4±216.2 + nBNI (κ) 108±3.63d N.D.3
(n = 5)2
Morphine 145.3± 6.86c 388.1±140.7 + cyp. (μ) 106.9± 2.65d N.D.3
(n = 7)1 (n = 5)1
– – + NTI (δ)
(n = 5)1 105.9± 3.95d N.D.3
(n = 5)2 118.8± 2.32 422.2±151.9 + nBNI (κ) N.D.4 N.D.4
DAMGO (μ) 165.3± 4.11 197±75.44 + cyp. (μ) 116.6± 5.24d > 1000
(n = 7)1 (n = 5)1
Delt II (δ) 128.9± 2.57 158.1±98.37 + NTI (δ) 103.7± 1.15d N.D.3
(n = 5)1 (n = 5)1
U-69593 (κ) + nBNI (κ)
(n = 6)2 131±2.63 69.74±18.34 (n = 5)2 108.7± 3.21d N.D.3
1 Performed in rat brain membrane homogenates.
2 Performed in guinea pig brain membrane homogenates.
3 The compound did not alter signiﬁcantly (One-way ANOVA, Dunnett's multiple comparison post hoc test) the basal activity (100%) of the G-protein, thus the EC50 value cannot be
interpreted.
4 Morphine alone displayed poor activity, therefore adding norbinaltorphimine was unnecessary.
Note: μ, δ and κ indicates the three classic opioid receptors; N.D.: not determined.
a P<0.001 compared to morphine and Delt II in rat brain membrane homogenates (One-way ANOVA, Tukey's multiple comparisons post hoc test).
b P<0.001 compared to morphine in guinea pig brain membrane homogenates (One-way ANOVA, Tukey's multiple comparisons post hoc test).
c P< 0.001 between rat and guinea pig brain homogenates with either 14-O-methylmorphine or morphine (unpaired t test, two-tailed P value).
d P< 0.001 compared to the corresponding agonist alone (unpaired t test, two-tailed P value).
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thus the maximum eﬃcacy of the novel morphine analogue was also
decreased signiﬁcantly in the presence of all the antagonists, similar to
morphine. However, the maximum eﬃcacy of 14-O-methylmorphine in
the presence of cyprodime was still signiﬁcantly diﬀerent from basal
activity similar to DAMGO and in contrast to morphine, but the potency
decreased more than 1000 nM (Table 2). Naltrindole, and norbi-
naltorphimine – similar to morphine – decreased the activity of 14-O-
methylmorphine to basal activity level (Table 2). The reduced activity
of the compounds in the presence of the antagonists are also clearly
demonstrated in the averaged concentration-response curve presented
in Fig. 4B and C.
3.2. Opioid agonist activity in mouse and rat vas deferens
In mouse vas deferens, 14-O-methylmorphine and DAMGO inhibited
the electrically-evoked mouse vas deferens muscle contractions in a
concentration dependent manner (Fig. 5). Morphine showed con-
centration-response curve of ceiling eﬀect (Fig. 5). The calculated EC50
(nM) values were the following: 52.55, 318.23 and 193.13 for 14-O-
methylmorphine, morphine and DAMGO, respectively (Table 3). In
comparison morphine only produced submaximal eﬀect. The average
Emax (%) values were: 86.04 for 14-O-methylmorphine, 58.36 for
morphine, and 95.94 for DAMGO (Table 3). The calculated Ke (nM)
values of naloxone against 14-O-methylmorphine, morphine and
DAMGO were: 1.78, 1.26 and 1.88, respectively (Table 3). The Ke va-
lues of norbinaltorphimine and naltrindole against 14-O-methylmor-
phine were 11.52± 1.14 (n = 4) and 14.59± 2.85 (n = 4), respec-
tively (not indicated in Table 3). On the other hand, the calculated Ke
values for norbinaltorphimine and naltrindole against morphine were
21.57±2.45 (n = 3) and 8.22± 1.50 (n = 4), respectively (not in-
dicated in Table 3).
In rat vas deferens bioassay, 14-O-methylmorphine similar to
DAMGO inhibited the muscle contractions in a concentration depen-
dent manner in contrast to morphine which did not have any eﬀect,
indicating lower eﬃcacy. EC50 (nM) values were: 270.04 for 14-O-
methylmorphine and 483.1 for DAMGO (Table 4).
3.3. Antinociceptive activity
To determine the antinociceptive properties of 14-O-methylmor-
phine, rat tail-ﬂick test was used. After s.c. administration the peak
eﬀect of 14-O-methylmorphine was achieved at 30 min, similarly to
morphine. 14-O-methylmorphine and morphine elicited a dose-depen-
dent antinociception. The calculated ED50 value at this time was 857
and 5259 (nmol/kg) for 14-O-methylmorphine and morphine, respec-
tively (Table 5A), indicating that 14-O-methylmorphine is a more po-
tent antinociceptive agent than morphine. Following i.c.v. administra-
tion the peak eﬀect of both 14-O-methylmorphine and morphine were
achieved after 30 min and the calculated ED50 value (nmol/rat) was
1.08 for 14-O-methylmorphine and 38.57 for morphine (Table 5B). The
s.c./i.c.v. ratio was 794 for 14-O-methylmorphine and 136 for mor-
phine. The antinociceptive eﬀect of both 14-O-methylmorphine and
morphine at 30 min after s.c. and icv. administration is indicated in
Fig. 6A and B, respectively.
3.4. Inhibitory eﬀect of systemic 14-O-methylmorphine and morphine on
gastrointestinal transit in rats
Fig. 7 depicts the inhibitory action of s.c. administered 14-O-me-
thylmorphine and morphine on the gastrointestinal passage of charcoal
suspension. The calculated inhibitory dose (ID50) and conﬁdence in-
terval (nmol/kg) was 2960 (1772–4943) for 14-O-methylmorphine and
8738 (4237–18021) for morphine. These results indicate that morphine
inhibited the gastrointestinal transit at 1.4 times higher dose than the
antinociceptive ED50, whereas 14-O-methylmorphine at 2.2 times
higher dose than its antinociceptive ED50 (see 3.3).
4. Discussion
This work for the ﬁrst time analyzed the pharmacological properties
and possible advantages of the novel opioid ligand, 14-O-methylmor-
phine over its parent molecule morphine or prototype µ-opioid receptor
selective peptide agonist, DAMGO in in vitro tests. The antinociceptive
eﬀect as well as the impact on rat intestinal transit of the test compound
was also measured in vivo, with the rat tail-ﬂick and charcoal meal
assays, respectively. We found that 14-O-methylmorphine is a µ-opioid
receptor agonist of higher aﬃnity, potency, eﬃcacy and anti-
nociceptive activity than morphine. The displayed aﬃnity of 14-O-
methylmorphine for µ-opioid receptor over δ-opioid receptor or к-
opioid receptor was assessed by applying competitive binding studies,
which have been reported as a good method to analyze the interaction
between drugs and their receptors (Leslie, 1987). This interaction is
expressed by the aﬃnity, which is described as the ability of the ligand
to bind to receptors. In these experiments, we used prototype ligands
Fig. 3. Binding aﬃnity of 14-O-methylmorphine (14-O-MeM) to µ-opioid receptor (A), δ-
opioid receptor (B) and к-opioid receptor (C) compared to morphine in competition
binding experiments performed in rat (A and B) and guinea pig (C) brain membrane
homogenate. For control the unlabeled form of the applied radioligands are also in-
dicated. All ﬁgures represent the speciﬁc binding of the corresponding radioligand (A:
[3H]DAMGO, B: [3H]Ile5,6-deltorphin II [IleDelt II], C: [3H]U-69593) in percentage
(means± S.E.M.) in the presence of increasing concentrations (0.1 nM-10 μM) of the
indicated unlabeled ligands. “Total” on the x-axis indicates the total speciﬁc binding of
the given radioligand, which is measured in the absence of the unlabeled compounds. The
level of total speciﬁc binding was deﬁned as 100% and is presented with a dotted line.
The Ki± S.E.M. values are presented in Table 1.
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for each opioid receptor subtypes (µ-, δ- and к-opioid receptor) to make
a comparison. 14-O-methylmorphine, and homology ligands were able
to inhibit the speciﬁc binding of [3H]DAMGO, [3H]Ile5,6-deltorphin II
and [3H]U-69593 to µ-, δ- and к-opioid receptor respectively. In opioid
research these radiolabeled ligands are well characterized and widely
used in the competitive binding studies to assess the aﬃnity of novel
opioids (Benyhe et al., 1992; Nevin et al., 1994; Spetea and
Schmidhammer, 2012). 14-O-methylmorphine showed high selectivity
and aﬃnity for µ-opioid receptor, which could be great advantage as
this opioid receptor subtype has a crucial role in antinociception
(McDonald, 2005). When compared to morphine, 14-O-methylmor-
phine displayed higher selectivity for the µ-opioid receptor than for the
δ-opioid receptor and in contrast to morphine the test compound
showed noticeable aﬃnity for к-opioid receptor. This additional
Fig. 4. Agonist activity of 14-O-methylmorphine (14-O-MeM) compared to morphine in the absence (A and C) or presence of cyprodime (cyp.), naltrindole (NTI) (B) and norbi-
naltorphimine (nBNI) (D) µ-, δ- and к-opioid receptor selective antagonists, respectively in [35S]GTPγS binding assays performed in rat (A and B) and guinea pig (C and D) brain
membrane homogenates. For comparison standard µ-, δ- and к-opioid receptor selective agonists, DAMGO, deltorphin II (Delt II) and U-69593, respectively are also presented in the
absence or presence of their corresponding opioid receptor selective antagonists. Figures represents the speciﬁc binding of [35S]GTPγS in percentage (means± S.E.M.) in the presence of
increasing concentrations (0.1 nM–10 µM) of the indicated ligands in the absence or presence of 10 μM of the indicated opioid antagonists. “Basal” on the x-axis indicates the basal
activity of the monitored G-protein (deﬁned as 100%, its level is presented as a dotted line), which is measured in the absence of the compounds and also represents the total speciﬁc
binding of [35S]GTPγS. The Emax and EC50± S.E.M. values are presented in Table 2.
Fig. 5. The inhibitory eﬀect of 14-O-methylmorphine (14-O-MeM) on electrically evoked
contractions of mouse vas deferens compared to morphine or DAMGO. Data are presented
as mean± S.E.M. The Emax and EC50± S.E.M. values are presented in Table 3. Experi-
ments were performed and analyzed as described in Sections 2.5.1 and 2.8.2, respec-
tively.
Table 3
The 50% eﬀective concentration (EC50) and the maximal eﬀect (Emax) of 14-O-methyl-
morphine (14-O-MeM), morphine and DAMGO in isolated mouse vas deferens.
Compounds Emax ± S.E.M. (%) EC50 ± S.E.M. (nM) Ke ± S.E.M. (nM)
14-O-MeM 86.04± 2.56a 52.55± 16.33b,c 1.78± 0.20
(n = 7) (n = 7) (n = 7)
Morphine1 58.36± 6.92 318.23± 29.0 1.26± 0.33
(n = 8) (n = 8) (n = 8)
DAMGO1 95.94± 1.74a 193.13± 49.36 1.88± 0.30
(n = 8) (n = 8) (n = 8)
1 (Lacko et al., 2012).
Ke Dissociation constant of naloxone.
a P< 0.001 compared to morphine (One-way ANOVA, Tukey's multiple comparisons
post hoc test).
b P< 0.01 compared to morphine (One-way ANOVA, Tukey's multiple comparisons
post hoc test).
c P<0.05 compared to DAMGO (One-way ANOVA, Tukey's multiple comparisons post
hoc test).
Table 4
The 50% eﬀective concentration (EC50) and the maximal eﬀect (Emax) of 14-O-methyl-
morphine (14-O-MeM) compared to morphine and DAMGO in isolated rat vas deferens.
Compounds Emax ± S.E.M. (%) EC50 ± S.E.M. (nM)
14-O-MeM 89.69± 3.54 270.04± 73.51
(n = 7) (n = 7)
Morphine No eﬀect N.D.
(n = 6)
DAMGO1 80.58± 3.74 483.1± 57.29
(n = 4) (n = 4)
N.D.: Not determined
1 (Lacko et al., 2012)
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receptorial activity might have signiﬁcant impact on the CNS functions
of the novel compound; it may enhance the µ-opioid receptor-induced
antinociceptive action (Kivell and Prisinzano, 2010), and in parallel
may reduce the euphoric property and abuse potential (Funada et al.,
1993).
The competition binding studies had only shown that the ligand has
aﬃnity for the receptors but to approve whether it is full agonist,
partial agonist or antagonist another assays were needed. Therefore,
functional [35S]GTPγS binding and mouse vas deferens assays were used
to estimate the agonist character of the novel compound and to com-
pare it to that of reference compounds. These assays are suitable to
determine both agonist potency and eﬃcacy, which are deﬁned in
terms of EC50 and Emax, respectively (Leslie, 1987; Strange, 2010). The
[35S]GTPγS binding assay monitors the ability of a test compound to
activate the G-protein, which is the ﬁrst and crucial step in GPCR sig-
naling. The mouse vas deferens bioassay represents a one step closer
approach to a more physiological circumstance for agonist activity
measurements compared to brain membrane homogenates in receptor
binding assays. In these studies, we found that 14-O-methylmorphine is
more potent than the reference compounds and showed full agonist
character indicated by the Emax value, similar to DAMGO and in con-
trast to morphine. DAMGO is known to be a full peptide agonist at µ-
opioid receptor (Gassaway et al., 2014; Hirning et al., 1985; Al-
Khrasani et al., 2001). Additionally, selective opioid receptor subtype
antagonists signiﬁcantly reduced the G-protein activity of 14-O-me-
thylmorphine, indicating that its agonist activity is mediated by either
the µ-, δ- and к-opioid receptor. However, the preference for µ-receptor
is already addressed in the binding assay. Cyprodime at higher test
concentration failed to totally reverse the maximal eﬀect (Emax)
achieved by 14-O-methylmorphine or DAMGO to the basal values. This
can be explained by the own activity of cyprodime which was 111.4%
(±2.12) based on our present results and earlier reports (Márki et al.,
1999). In addition, we have to take into the account the aﬃnity, be-
cause reversible interaction was occurred between 14-O-methylmor-
phine or DAMGO and cyprodime, and the concentration dictates the
observed eﬀect. That means increasing the concentration of cyprodime
might result in an Emax close to basal activity or to that achieved by
cyprodime alone. In mouse vas deferens, the Ke values of naloxone (a
non-selective opioid antagonist) against morphine, DAMGO and 14-O-
methylmorphine were within the range of 1.26–1.80 nM and there were
no signiﬁcant diﬀerences between the values. These results indicate
Table 5
(A and B). Antinociceptive potencies (ED50) of 14-O-methylmorphine (14-O-MeM) and
morphine against radiant heat induced nociception in rat tail-ﬂick test after 30, 60 and
120 min of s.c. administration (5/A) and after 10, 20, 30 and 60 min of i.c.v. adminis-
tration (5/B).
A
Compounds ED50 (sc., nmol/kg)
Time after sc. administration (min)
30 60 120
14-O-MeM 857a 1345 –
(451–1629) (743–2437)
Morphine 5259a 6270 18,845
(3637–7603) (4344–9049) (11,279–31,486)
B
Compounds ED50 (icv., nmol/animal)
Time after icv. administration (min)
10 20 30 60
14-O-MeM 1.12 1.15 1.08a 2.85
(0.63–1.96) (0.68–1.95) (0.64–1.80) (1.5–5.41)
Morphine – 55.371 38.57a,1 49.151
(32.04–94.87) (22.08–67.49) (28.93–83.67)
Data in parentheses are 95% conﬁdence limits. At least 5 animals per dose group and 3–4
doses were used for each ED50 determinations.
1 (Lacko et al., 2012).
a Peak of eﬀect.
Fig. 6. The peak antinociceptive eﬀect (after 30 min) of 14-O-methylmorphine (14-O-MeM) and morphine in rat tail-ﬂick test after s.c. (A) and i.c.v. (B) administration. Data represent
means± S.E.M. and were analyzed as described in Section 2.8.3. The experiments were performed according to Section 2.6.
Fig. 7. The eﬀect of 14-O-methylmorphine (14-O-MeM) on rat gastrointestinal transit
compared to morphine and control (saline). The ﬁgure represents the inhibition of gas-
trointestinal transit in percentage (means± S.E.M.) of total length compared to saline
treated group (control) in the presence of 14-O-MeM and morphine in the indicated
dosages. *: indicates the signiﬁcant diﬀerence compared to control (One-way ANOVA,
Tukey's multiple comparisons post hoc test, P< 0.001). The experiment was performed
and analyzed as discussed in Sections 2.7 and 2.8.3, respectively.
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that all compounds are µ-opioid receptor selective agonists and corre-
spond well with our competition binding results and with previous data
regarding to DAMGO and morphine reported by our or other teams
(Khalefa et al., 2013; Lacko et al., 2012; Miller et al., 1986). Of note, the
Ke values of norbinaltorphimine was signiﬁcantly lower when tested
against 14-O-methylmorphine compared to against morphine.
Since these experiments were carried out in brain homogenates and
mouse vas deferens, and these tissues have been reported to host opioid
receptors of high reserve (Leslie, 1987), therefore we extended our
study to test the action of test compound in rat vas deferens. Rat vas
deferens hosts μ-opioid like receptors of low reserve (Al-Khrasani et al.,
2007; Miller et al., 1986; Smith and Rance, 1983) and opioid of high
eﬃcacy will act as full agonist. Our ﬁndings indicate that 14-O-me-
thylmorphine similar to DAMGO but not to morphine produced high
eﬃcacy. The full and partial agonist character of an opioid agonist is an
important issue, since many reports described that a decrease in anti-
nociceptive eﬃcacy of currently used opioid is a consequence of de-
crease in opioid receptor reserve (Al-Khrasani et al., 2001, 2007;
Khalefa et al., 2013; Riba et al., 2010). Therefore, only opioid of high
eﬃcacy (having spare receptors) will be able to produce antinocicep-
tion by chronic administration without substantial loss of eﬀect. De-
crease in opioid receptor has been observed in spinal diabetic rats
(Shaqura et al., 2013), suﬀering of neuropathic pain. In such pain, we
assume that opioids of high eﬃcacy might be of pharmacological va-
lues.
Finally, we were curious in the antinociceptive and side eﬀect of the
novel compound, since the in vitro data not always ﬁt the researcher's
expectation when the study carried out in a complex biological system.
Therefore, we extended our study to determine the antinociceptive
action of 14-O-methylmorphine in vivo, as well as its inhibitory eﬀect on
gastrointestinal transit. For this study, acute heat-induced pain (rat tail-
ﬂick) and charcoal meal tests were chosen. In good accordance with the
in vitro ﬁndings, 14-O-methylmorphine increased the pain threshold in
a dose dependent manner and proved to be a more potent anti-
nociceptive agent than morphine when injected systemically or cen-
trally. Interestingly, the test compound compared to morphine showed
a somewhat weaker inhibitory action on gastrointestinal peristalsis.
This result was seen when ratios of antinociception (ED50) and anti-
transit (ID50) values for morphine and 14-O-methylmorphine were
compared. These results suggest that the test compound has less pro-
nounced gastrointestinal side eﬀects, though we did not expect it, since
it showed high eﬃcacy in in vitro assays, implying that it behaves as a
full agonist. It is noteworthy that similar promising favorable proﬁle
had also been reported by Holtman and coworkers for morphine-6-O-
sulfate (Holtman et al., 2010), but in its case the partial agonistic
property might explain the mild gastrointestinal inhibitory action
(Lackó et al., 2012; Al-Khrasani et al., 2001). Morphine, on the other
hand, is also a partial agonist, but induced more pronounced antitransit
eﬀect than the other two derivatives. Further studies are needed to
verify these diﬀerences and their translational relevance.
The development of 14-alkyloxymorphinan analogues was ﬁrst re-
presented by the synthesis of 14-O-methyloxymorphone
(Schmidhammer et al., 1984) followed by others (Spetea and
Schmidhammer, 2012). Similar strategy was carried out for the synth-
esis of 14-O-methylmorphin-6-O-sulfate (Lacko et al., 2012) and here
for 14-O-methylmorphine. 14-O-methylmorphine similar to 14-O-me-
thyloxymorphone and 14-O-methylmorphin-6-O-sulfate displayed im-
proved aﬃnity, agonist activity and antinociceptive potency compared
to their parent compound (oxymorphone and morphine-6-O-sulfate,
respectively) (Lacko et al., 2012; Spetea and Schmidhammer, 2012).
Questions might be raised around clinical value of such analogues.
MOR agonists of such pharmacological properties (high potency and
eﬃcacy) can be advantageous in the terms of clinical use, because as
above mentioned, animal models of neuropathic pain have been re-
ported to display decrease in the µ-opioid receptor reserve (Shaqura
et al., 2013). Therefore, we can assume that opioid agonists of high
eﬃcacy might be beneﬁcial in such pain conditions. Also, there is the
possibility that these compounds have a better tolerance proﬁle prob-
ably because of their high eﬃcacy (Kiraly et al., 2015). Although the
antinociceptive property of the test compound is promising, the noticed
interaction with κ-opioid receptor and other not determined safety
proﬁles (respiratory depression and addiction) will be studied in further
pharmacological, pharmacokinetic and toxicological assays in the fu-
ture.
5. Conclusion
We investigated the highly eﬀective novel compound 14-O-me-
thylmorphine. Our results strengthen the hypothesis and our previous
ﬁndings that these kind of structure modiﬁcations of morphine lead to a
better pharmacological proﬁle in terms of eﬃcacy and potency.
Additionally, 14-O-methylmorphine showed high selectivity for µ-
opioid receptor and was highly eﬀective antinociceptive agent of de-
creased antitransit eﬀect compared to morphine after systemic admin-
istration. These new agents can be a new way to alleviate pain in
conditions like neuropathic or inﬂammatory pain syndromes when it's a
major challenge to treat with the drugs that are in clinical practice.
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